Aldeyra Therapeutics, Inc.
NASDAQ:ALDXBiotechnology
+$0.06 today
- Market cap
- $54.28M
- Beta
- 1.19
- P/E (TTM)
- -4.2
- EPS (TTM)
- -$0.45
Volume 1.45M
Average 2.13M
ALDX Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Aldeyra Therapeutics, Inc.NASDAQ: ALDX
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income declines year over year
Q1 FY2026 net income of $3.45M (cash outflow) fell 65.2% year over year, behind the -52.6% change in trailing-twelve-month net income. Sequentially, it fell 46.6% from the prior quarter. Over 3 fiscal years it compounded at -18.3% a year.
Context
- Net income grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 2 analysts of -$24.32M (-28.1%) for the fiscal year ending Dec 2026, a step up from the -39.4% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$3.45M-46.6% QoQ
- Last fiscal yearDec 2025
- -$33.85M-39.4% YoY
- LTMMar 2026
- -$27.37M-52.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -65.2% | -35.2% | +30.1 pp |
| 1 year | -39.4% | -28.1% | +11.3 pp |
| 3-year CAGR | -18.3% | -62.4% | -44.1 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (33.85M) USD
- Year-over-year change
- +39.4%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (33.85M) | +39.4% |
| FY2024 | 2024-12-31 | (55.85M) | -48.8% |
| FY2023 | 2023-12-31 | (37.54M) | +39.5% |
| FY2022 | 2022-12-31 | (62.02M) | -7.4% |
| FY2021 | 2021-12-31 | (57.78M) | — |
Net Income vs competitors
How ALDX compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -52.6% is the lowest of 10, against a peer median of +17.3%.
- Over three fiscal years its annual growth of -18.3% compares with a peer median of +23.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $156.4M USD | +7.6% | +77.4% | — | |
| LTM Mar 2026 | $145.44M USD | — | +20.7% | 15782.6% | |
| LTM Mar 2026 | $74.31M USD | +17.6% | +31.7% | — | |
| LTM Dec 2025 | CHF 70.34M CHF | +38.1% | -1.7% | 1968.6% | |
| LTM Mar 2026 | $67.27M USD | +11.1% | -11.8% | 98.8% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $58.44M USD | +17.3% | +35.2% | — |
| LTM Mar 2026 | $54.42M USD | +37.5% | +26.7% | — | |
| LTM Mar 2026 | $35.71M USD | -24.3% | -0.3% | 7142.0% | |
GNLXGenelux Corporation | LTM Mar 2026 | $33.58M USD | +13.8% | +83.4% | 419762.5% |
| LTM Mar 2026 | $27.37M USD | -52.6% | -18.3% | — | |
| LTM Mar 2026 | $5.23M USD | +106.0% | -28.4% | 2.4% | |
| Peer median (excluding ALDX) | — | +17.3% | +23.7% | 4555.3% | |
Competitors are the stored peer set for ALDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (57.78M) | (62.02M) | (37.54M) | (55.85M) | (33.85M) |
| Depreciation & Amortization | 264.18K | 258.71K | 262.78K | 249.62K | 251.99K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 7.11M | 8.29M | 5.75M | 7.97M | 6.09M |
| Change in Working Capital | 7.44M | (3.44M) | 861.18K | 5.91M | (5.18M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 638.06K | (886.08K) | 1.2M | (1.16M) | (21.99K) |
| Other Working Capital | 6.8M | (2.56M) | (343.25K) | 7.07M | (5.16M) |
| Other Non-Cash Items | 409.47K | 283.91K | 339.65K | (1.49M) | (664.43K) |
| Operating Cash Flow | (42.56M) | (56.64M) | (30.33M) | (43.21M) | (33.35M) |
| Capital Expenditures | (7.81K) | (16.32K) | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 16.32K | 0 | 0 | 0 |
| Purchases of Investments | 0 | (92.94M) | 0 | (96.92M) | (40.26M) |
| Sales of Investments | 0 | 63M | 30M | 52M | 88M |
| Other Investing Activities | 0 | (16.32K) | 0 | 0 | 0 |
| Investing Cash Flow | (7.81K) | (29.95M) | 30M | (44.92M) | 47.74M |
| Debt Repayment | 0 | 0 | (1.04M) | (292.5K) | 0 |
| Common Stock Issued | 189.81M | 1.22M | 305.23K | 121.08K | 1.12M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 4.68M | 0 | (532.95K) | 0 | (444) |
| Financing Cash Flow | 194.5M | 1.22M | (1.27M) | (171.42K) | 1.12M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 151.93M | (85.37M) | (1.6M) | (88.3M) | 15.51M |
| Free Cash Flow | (42.56M) | (56.65M) | (30.33M) | (43.21M) | (33.35M) |
Aldeyra Therapeutics, Inc.
NASDAQ:ALDX
Intrinsic Alpha fair value
Locked
Current Price
$0.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.